CYRAMZA

This brand name is authorized in Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug CYRAMZA contains one active pharmaceutical ingredient (API):

1 Ramucirumab UNII D99YVK4L0X - RAMUCIRUMAB

Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced angiogenesis. As a result, ramucirumab inhibits ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components, including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and migration of human endothelial cells. Read about Ramucirumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CYRAMZA Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FG02	Ramucirumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Discover more medicines within L01FG02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 507616050019702, 507616050019802
Country: CA	Health Products and Food Branch	Identifier(s): 02443805
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 53-MBE-0416
Country: EE	Ravimiamet	Identifier(s): 1674301, 1674312, 1674323
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 114957001, 114957001IP, 114957003, 114957003IP
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 180634, 575246
Country: FR	Base de données publique des médicaments	Identifier(s): 63848228
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 284694, 287914, 383722, 392347
Country: HK	Department of Health Drug Office	Identifier(s): 64421, 64422
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7805, 7806
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291429A1023, 4291429A2020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1075373, 1075374, 1075375
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 122777, 122785
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 18076, 18077
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100335298
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W61463001
Country: SG	Health Sciences Authority	Identifier(s): 15035P, 15036P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699673765143, 8699673765150, 8699673765167
Country: US	FDA, National Drug Code	Identifier(s): 0002-7669, 0002-7678